plaque psoriasis, severe recalcitrant
Rheumatology · 2017–2017
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methotrexate Treatment of severe, recalcitrant, active rheumatoid arthritis or severe, recalcitrant, disabling psoriasis when methotrexate oral tablets are unsuitable. | Mar 2017 | Recommended with restriction | 21 individuals Creaky Joints Australia · Arthritis Support Group |
Who spoke
Creaky Joints Australia · Arthritis Support Group
What the PBS pays
$20M in government benefit over 2024–25, across 445,602 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| methotrexate | $19.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.